Kilitch Drugs to Divest Ethiopian Subsidiary Stake for USD 12.86M via EGM Approval
Kilitch Drugs India Ltd 路 Extra Ordinary General Meeting 路 23 Oct 2026, 10:45 pm
Kilitch Drugs to Divest Ethiopian Subsidiary Stake for USD 12.86M via EGM Approval Kilitch Drugs (India) Ltd. has convened an EGM on 16th Nov'26 to approve the divestment of its entire stake in Ethiopian subsidiary, Kilitch Estro Biotech PLC (KEB), to HarmeeCare Pharmaceuticals. Prior to the sale, Kilitch will convert up to INR 57.00 crore of outstanding debt into KEB equity, raising its holding from 67.00% to 89.17%. The total transaction value is USD 14.00M, with Kilitch receiving USD 12.855M. Net proceeds will fund loan repayments, interest reduction, and expansion of its Pen manufacturing facility in India.
Original exchange filing (PDF)
More announcements from Kilitch Drugs India Ltd
- We are submitting Scrutinizer''s Report for evoting of EGM 路 16 Nov 2026
- Proceeding of EGM held today i.e. 16th November, 2026 路 16 Nov 2026
- Intimation under regulation 30 of the SEBI LODR regulations 2015, corrigendum to the Notice of Extra Ordinary General Meeting 路 13 Nov 2026
- We are submitting herewith the rectification of typo error in the outcome of Board meeting dated 22nd October, 2026 路 13 Nov 2026
- We are submitting herewith the outcome of the Board meeting 路 07 Nov 2026
- Kilitch Drugs (India) Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 07 Nov 2026
- Submitting unaudited financials results for quarter ended 30.09.2026 路 07 Nov 2026
- KILITCH DRUGS (INDIA) LIMITED has informed the Exchange about Board Meeting to be held on 06-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 06 Nov 2026
